Leerink analyst Faisal Khurshid initiated coverage of Ironwood with a Market Perform rating and $5 price target. The firm notes that the forthcoming launch of apraglutide in SBS might extend Ironwood’s positive cash flows beyond the Linzess LOE, but uncertainties on apraglutide’s commercial picture coupled with the company’s high debt load, sparse catalyst path, and commercial headwinds for Linzess keep Leerink on the sidelines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood price target lowered to $10 from $14 at Craig-Hallum
- Ironwood price target lowered to $12 from $14 at Wells Fargo
- Warner Bros. writes down networks, Eli Lilly posts beat: Thursday Buzz
- Ironwood downgraded to Equalweight from Overweight at Capital One
- Palantir partners with Microsoft, Eli Lilly posts beat: Morning Buzz